As of Aug 18
| +0.10 / +0.46%|
The 7 analysts offering 12-month price forecasts for Acorda Therapeutics Inc have a median target of 22.00, with a high estimate of 35.00 and a low estimate of 18.00. The median estimate represents a +0.46% increase from the last price of 21.90.
The current consensus among 8 polled investment analysts is to Hold stock in Acorda Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.